German NEXUS acquires Omilon: Aims to build a leading European player in AI and clinical documentation

The German health technology company NEXUS AG is acquiring the Scandinavian technology company Omilon. The acquisition marks a strategic move to strengthen Europe’s position in AI based clinical documentation, while at the same time providing Omilon with a platform for further expansion across Europe.

The market for speech and AI in healthcare is growing rapidly. An increasing number of hospitals, clinics and municipalities are adopting speech technology to streamline documentation, reduce time spent on administrative tasks and free up capacity among healthcare professionals. At the same time, requirements for responsible use of artificial intelligence, data security and regulatory compliance are becoming more stringent.

Without seamless integration, scalability stalls

The major challenge has been integrating new, modern and responsible technology with existing EHR and professional systems in complex IT environments. This is where Omilon has positioned itself.

In recent years, the company has built a solid foothold in Scandinavia with its integration platform Omilon Connect, a middleware technology that enables speech recognition, dictation and generative AI to be integrated directly into existing electronic health record systems, professional systems and clinical workflows. The solution makes it possible to convert speech into structured, reusable clinical documentation, also in environments without modern API structures.

In doing so, Omilon has solved one of the biggest barriers to scaling AI in healthcare, namely practical and secure implementation within existing systems. The solution is already scaled in parts of the Scandinavian healthcare sector. Europe is next.

Unique integration technology

NEXUS, a German healthcare IT company with operations across several European countries, is an established provider of clinical information systems for hospitals, rehabilitation and care institutions. In recent years, the company has pursued a clear strategy of integrating artificial intelligence into clinical workflows.

Through the acquisition, NEXUS gains access to integration technology that can accelerate the rollout of responsible AI at scale.

“The integration of generative AI into clinical practice is a central part of our product strategy. With Omilon, we gain proven integration expertise and an experienced team within speech and AI based documentation,” says Ingo Behrendt, CEO of NEXUS.

Omilon already collaborates with players such as Tandem Health, Corti and Microsoft’s health technology ecosystem, and has initiated the rollout of its technology in several European markets. With NEXUS backing the company, this expansion will gain significantly greater distribution power.

Strengthening the Nordics, opening Europe

For NEXUS, the acquisition means a stronger foothold in Scandinavia, a market characterized by high digital maturity and early adoption of AI in healthcare.

For Omilon, it provides access to an established European distribution network and a broad customer base within hospitals and specialist healthcare services.

“Together with NEXUS, we can make the integration platform available to far more healthcare providers across Europe and contribute to faster adoption of responsible AI in clinical practice,” says Nicolay Moulin, CEO of Omilon.

Existing customer and partner relationships will continue as before.

Verdane realises investment in Omilon

Erling Amble, Director at Verdane, said: "We're proud to have partnered with Omilon for the last six years, strengthening its market leadership and enabling administrative efficiency in public healthcare across Scandinavia, while positioning it for further European expansion. Omilon is a great example of the types of companies Verdane is looking to back: growing European companies building a more sustainable future.

Throughout our partnership, we worked closely with the team to invest in product development, organisational capabilities and sustainable growth, supporting Omilon in scaling its operations while ensuring a strong end-user and technology focus. With its industrial expertise and strategic focus, Nexus AG is well placed to build on the strong foundation established over the past years and to continue driving long-term growth for the business.”

A European response in health technology

The acquisition takes place at a time when European health authorities are calling for stronger regional technology providers to ensure data sovereignty, regulatory control and competitiveness.

With the combination of NEXUS’ broad system portfolio and Omilon’s integration technology for responsible AI, this establishes what could become one of the more prominent European initiatives within clinical documentation and speech based technology.

“The ambition is to make modern, responsible and efficient AI available to the entire European healthcare sector, not as pilot projects, but at full scale,” adds Ingo Behrendt, CEO of NEXUS.

The parties have agreed not to disclose the financial terms of the transaction.

For more information, contact

Nicolay Moulin

Chief Executive Officer, Omilon Group
+47 905 91 983
nicolay.moulin@omilon.com